Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy.

abstract：:The greatest risk factor for the development of cervical and other cancers that have been linked to the human papillomavirus (HPV) family is the persistence of the virus. To persist for the decades required to develop HPV-related cancers, the virus must escape host immunity. HPV is a simple DNA virus that has evolved ...

journal_title：Current cancer drug targets

authors： Kanodia S,Fahey LM,Kast WM

更新日期：2007-02-01 00:00:00

abstract：:Various signal transduction pathways have been implicated in the pathogenesis of chronic lymphocytic leukemia (CLL), which is characterized by the progressive accumulation of monoclonal CD5+ B cells in the blood. B cell receptor (BCR) signaling appears to have a crucial role in disease onset and is thought to be induc...

journal_title：Current cancer drug targets

authors： Muggen AF,Singh SP,Hendriks RW,Langerak AW

更新日期：2016-01-01 00:00:00

abstract：:Malignant gliomas are frequently chemoresistant and this resistance seems to depend on at least two mechanisms. First, the poor penetration of many anticancer drugs across the blood-brain barrier (BBB), the blood-cerebrospinal fluid barrier (BCSFB) and blood-tumor barrier (BTB), due to their interaction with several A...

journal_title：Current cancer drug targets

authors： Declèves X,Amiel A,Delattre JY,Scherrmann JM

更新日期：2006-08-01 00:00:00

abstract：:Coordination between the amplification of the fibroblast growth factor FGF19, overexpression of its corresponding receptor FGFR4, and hyperactivation of the downstream transmembrane enzyme β-klotho has been found to play pivotal roles in mediating tumor development and progression. Aberrant FGF19-FGFR4 signaling has b...

journal_title：Current cancer drug targets

authors： Lang L,Shull AY,Teng Y

更新日期：2019-01-01 00:00:00

abstract：:Glioma-associated oncogenes (GLIs) are zinc finger protein family members and downstream regulatory factors of the classic Hedgehog (Hh) signaling pathway. GLI proteins influence the growth and development of organisms and aid in tissue repair. However, aberrant expression of the GLI family member GLI1 promotes carcin...

journal_title：Current cancer drug targets

authors： Wu J,Di D,Zhao C,Liu Y,Chen H,Gong Y,Zhao X,Chen H

更新日期：2018-01-01 00:00:00

abstract：:Tumor heterogeneity within various cancer types including breast carcinoma is pivotal in the manifestations of tumor hallmarks. Tumor heterogeneity is seen as a common landscape where intra-tumoral components including cellular and non-cellular factors create an interface with outside environment that leads to the uni...

journal_title：Current cancer drug targets

authors： Tandon I,Sharma NK

更新日期：2019-01-01 00:00:00

abstract：:Targeted therapies focus on signaling pathways in cancer cells and other molecular processes involved in oncogenesis. Recent approaches affect the following major groups: the epidermal growth factor receptor (EGFR)-family, angiogenesis, the eicosanoid pathway, the PKC/ Ras/ MAPK pathway, the proteasome and inducers of...

journal_title：Current cancer drug targets

authors： Auberger J,Loeffler-Ragg J,Wurzer W,Hilbe W

更新日期：2006-06-01 00:00:00

abstract：:The total expression profiles of two medulloblastoma cell lines resistant to the preactivated form of cyclophosphamide (4-hydroperoxycyclophosphamide, 4-HC) were examined using the Affymetrix GeneChip U133A array. Our primary objective was to look for possible genes, other than the well-studied aldehyde dehydrogenases...

journal_title：Current cancer drug targets

authors： Bacolod MD,Lin SM,Johnson SP,Bullock NS,Colvin M,Bigner DD,Friedman HS

更新日期：2008-05-01 00:00:00

abstract：:Autophagy is an intracellular lysosomal/vacuolar degradation system, in which the inner cytoplasmic cell membrane is degraded by the lysosomal hydrolases, followed by the resulting products released back into the cytosol. It is involved in many physiological processes which are crucial for cell growth and survival. Ho...

journal_title：Current cancer drug targets

authors： Zhou X,Yue GG,Tsui SK,Pu J,Fung KP,Lau CB

更新日期：2018-01-01 00:00:00

abstract：:The actin microfilament network is important in maintaining cell shape and function in eukaryotic cells. It has a multitude of roles in cellular processes such as cell adhesion, motility, cellular signalling, intracellular trafficking and cytokinesis. Alterations in the organisation of the cytoskeleton and changes in ...

journal_title：Current cancer drug targets

authors： Stehn JR,Schevzov G,O'Neill GM,Gunning PW

更新日期：2006-05-01 00:00:00

abstract：BACKGROUND AND AIM:Translational data suggest that nucleoside transporters, in particular human equilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. The aim of this study was to retrospectively determine patient...

journal_title：Current cancer drug targets

authors： Santini D,Schiavon G,Vincenzi B,Cass CE,Vasile E,Manazza AD,Catalano V,Baldi GG,Lai R,Rizzo S,Giacobino A,Chiusa L,Caraglia M,Russo A,Mackey J,Falcone A,Tonini G

更新日期：2011-01-01 00:00:00

abstract：:There is an emerging paradigm shift in oncology that seeks to emphasize molecularly targeted approaches for cancer prevention and therapy. Chalcones (1,3-diphenyl-2-propen-1-ones), naturally-occurring compounds with widespread distribution in spices, tea, beer, fruits and vegetables, consist of open-chain flavonoids i...

journal_title：Current cancer drug targets

authors： Jandial DD,Blair CA,Zhang S,Krill LS,Zhang YB,Zi X

更新日期：2014-01-01 00:00:00

abstract：:Despite remarkable progress that has been made in the recent years in the treatment of gastrointestinal tumors, in particular colorectal cancer, the prognosis of pancreatic cancer remains dismal. Five years after diagnosis almost all patients have died. At early stages of the disease surgery is the only modality to ac...

journal_title：Current cancer drug targets

authors： Porzner M,Seufferlein T

更新日期：2011-07-01 00:00:00

abstract：:Membranous Met is classically identified with its role in cancer metastases, while nuclear Met is associated with a more invasive, aggressive and proliferative form of cancer. Full-length Met or N-terminal transmembrane domain cleaved Met can translocate into nucleus in a cell growth and pH dependent but both ligand-d...

journal_title：Current cancer drug targets

authors： Xie Y,Istayeva S,Chen Z,Tokay T,Zhumadilov Z,Wu D,Hortelano G,Zhang J

更新日期：2016-01-01 00:00:00

abstract：:Constitutive activation of the EGFR/RAS/PI3K cell-signaling pathway that may occur through molecular aberrations in core pathway components occurs in many solid tumours, including colorectal cancer(CRC), non-small-cell lung cancer(NSCLC) and breast cancer. Predictive biomarkers of response to therapeutics targeting th...

journal_title：Current cancer drug targets

authors： Barton S,Starling N,Swanton C

更新日期：2010-12-01 00:00:00

abstract：:Though modern available cancer therapies are effective, they possess major adverse effects, causing non-compliance to patients. Furthermore, the majority of the polymeric-based medication platforms are certainly not universally acceptable, due to their several restrictions. With this juxtaposition, lipid-based medicat...

journal_title：Current cancer drug targets

authors： Rajpoot K

更新日期：2020-01-01 00:00:00

abstract：:Cancer drug therapy is undergoing a major transition from the previous pregenomic cytotoxic era to the new postgenomic era. Future mechanism-based therapeutic agents will increasingly be designed to act on molecular targets that are causally involved in the malignant progression of human cancers. Such agents are predi...

journal_title：Current cancer drug targets

authors： Workman P

更新日期：2001-05-01 00:00:00

abstract：:Degradation of extracellular matrix is crucial for malignant tumor growth, invasion, metastasis and angiogenesis. Matrix metalloproteinases (MMPs) are a family of zinc-dependent neutral endopeptidases collectively capable of degrading essentially all matrix components. Elevated levels of distinct MMPs can be detected ...

journal_title：Current cancer drug targets

authors： Vihinen P,Ala-aho R,Kähäri VM

更新日期：2005-05-01 00:00:00

abstract：BACKGROUND:Improving poorly soluble drugs into druggability was a major problem faced by pharmaceutists. Nanosuspension can improve the druggability of insoluble drugs by improving the solubility, chemical stability and reducing the use of additives, which provided a new approach for the development and application of ...

journal_title：Current cancer drug targets

authors： Cao Y,Wei Z,Li M,Wang H,Yin L,Chen D,Wang Y,Chen Y,Yuan Q,Pu X,Zong L,Duan S

更新日期：2019-01-01 00:00:00

abstract：:Over the past two decades, a number of chemical entities have been investigated in the continuing quest to reverse P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in cancer cells and some have undergone clinical trials, but currently none are in clinical use. Unfortunately, most of these agents suffer clinic...

journal_title：Current cancer drug targets

authors： Mayur YC,Peters GJ,Prasad VV,Lemo C,Sathish NK

更新日期：2009-05-01 00:00:00

abstract：:Angiotensin II (Ang II), a main effector peptide of the renin-angiotensin system (RAS), mediates a hormonal action in the maintenance of blood pressure and electrolyte levels, and thus fluid homeostasis. Ang II also mediates paracrine, autocrine and/or intracrine actions in the control of various specific functions of...

journal_title：Current cancer drug targets

authors： Lau ST,Leung PS

更新日期：2011-05-01 00:00:00

abstract：:An apparent low prevalence of cancer in hypertensive patients receiving angiotensin converting enzyme inhibitors is reported; however, the molecular mechanisms have not been elucidated. Angiotensin-II (Ang-II) is well known to be associated with hypertension, as a main peptide of the renin-angiotensin system, and its ...

journal_title：Current cancer drug targets

authors： Uemura H,Nakaigawa N,Ishiguro H,Kubota Y

更新日期：2005-08-01 00:00:00

abstract：:Cetuximab (IMC-C225, Erbitux ImClone Systems Inc, New York, NY) is a recombinant, human/mouse chimeric monoclonal antibody (MAb) that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of epidermal g...

journal_title：Current cancer drug targets

authors： Vincenzi B,Zoccoli A,Pantano F,Venditti O,Galluzzo S

更新日期：2010-02-01 00:00:00

abstract：:Bisphosphonates are the standard of care for preventing skeletal morbidity and treating hypercalcemia of malignancy in patients with bone metastases. Zoledronic acid (intravenous; 4 mg monthly) is approved to prevent skeletal-related events (SREs) in patients with bone metastases from several tumor types, and can impr...

journal_title：Current cancer drug targets

authors： Gnant M

更新日期：2009-11-01 00:00:00

abstract：:The genomic characterization of acute myeloid leukemia (AML) by DNA sequencing has illuminated subclasses of the disease, with distinct driver mutations, that might be responsive to targeted therapies. Approximately 15-23% of AML genomes harbor mutations in one of two isoforms of isocitrate dehydrogenase (IDH1 or IDH2...

journal_title：Current cancer drug targets

authors： Becker JS,Fathi AT

更新日期：2020-01-01 00:00:00

abstract：:Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders of hematopoietic progenitors manifest by cytopenias, bleeding, infection, and potential for progression to acute myelogenous leukemia. The wide spectrum of clinical manifestations, including variability in illness severity and potential for ...

journal_title：Current cancer drug targets

authors： Warlick ED,Smith BD

更新日期：2007-09-01 00:00:00

abstract：:The Jun oncoprotein is a major component of the transcription factor complex AP-1, which regulates the expression of multiple genes essential for cell proliferation, differentiation and apoptosis. Constitutive activation of endogenous AP-1 is required for tumor formation in avian and mammalian cell transformation syst...

journal_title：Current cancer drug targets

authors： Hartl M,Bader AG,Bister K

更新日期：2003-02-01 00:00:00

abstract：:The evolution of genomic research enabled the genetic and molecular profiling of breast cancer and revealed the profound complexity and heterogeneity of this disease. Subtypes of breast cancer characterized by mutations and/or amplifications of some proto-oncogenes are associated with an increased rate of recurrence a...

journal_title：Current cancer drug targets

authors： Guerram M,Hamdi AM,Zhang LY,Jiang Z

更新日期：2017-01-01 00:00:00

abstract：:Polyisoprenylated proteins (PPs) methylation by polyisoprenylated protein methyl transferase (PPMTase) is counteracted by polyisoprenylated methylated protein methyl esterase (PMPMEase). This is the only reversible step of the polyisoprenylation pathway as the relative amounts of the acid and ester forms are determine...

journal_title：Current cancer drug targets

authors： Duverna R,Ablordeppey SY,Lamango NS

更新日期：2010-09-01 00:00:00

abstract：:Castration-resistant prostate cancer remains incurable and a major cause of mortality worldwide. The absence of effective therapeutic approaches for advanced prostate cancer has led to an intensive search for novel treatments. Emerging nanomedical approaches have shown promising results, in vitro and in vivo, in impro...

journal_title：Current cancer drug targets

authors： Katsogiannou M,Peng L,Catapano CV,Rocchi P

更新日期：2011-10-01 00:00:00